866-997-4948(US-Canada Toll Free)

Alpharadin (Prostate Cancer) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Cancer

No. of Pages : 57 Pages


Alpharadin (Prostate Cancer) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Alpharadin (Prostate Cancer) Forecast and Market Analysis to 2022”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Alpharadin (radium-223 chloride) is an alpha-pharmaceutical being developed by Algeta and Bayer for the treatment of CRPC with bone metastases. It is calcium mimetic that localizes to the bone and delivers radiation directly to bone metastases by emitting an alpha particle. It is the most advanced prostate cancer drug in the pipeline to have shown efficacy at both preventing SREs and prolonging patient overall survival, and is also associated with mild adverse events. Alpharadin is administered by IV infusion once every four weeks. The FDA has granted it a fast-track designation for this indication.

Scope

  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Alpharadin including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Alpharadin for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Alpharadin performance 
  • Obtain sales forecast for Alpharadin from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.1.3 Prognosis 12
3.1.4 Quality of Life 13
3.2 Symptoms 13

4 Disease Management 14
4.1 Diagnosis and Referral Overview 14
4.2 Treatment Overview 16
4.2.1 Conservative Management Strategies 20
4.2.2 Localized Treatments 21
4.2.3 Hormone Therapy 22
4.2.4 Drug Therapies 24

5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27

6 Opportunity and Unmet Need 30
6.1 Overview 30
6.2 Efficacy at Prolonging Overall Survival 31
6.3 Safety 31
6.4 Mitigation of Symptoms 32
6.5 Cost 32
6.6 Convenient Routes of Administration 32
6.7 Accurate Diagnostic Tests and Surveillance Tools 33
6.8 Unmet Needs Gap Analysis 33
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 34

7 Pipeline Assessment 35
7.1 Overview 35
7.2 Promising Drugs in Clinical Development 36

8 Alpharadin (radium-223 chloride) 38
8.1 Overview 38
8.2 Efficacy 39
8.3 Safety 39
8.4 Dosing and Formulation 40
8.5 Potential Clinical Positioning 40
8.6 Potential Commercial Positioning 41
8.7 Pricing and Reimbursement 41
8.8 SWOT Analysis 42
8.9 Forecast 43

9 Appendix 44
9.1 Bibliography 44
9.2 Abbreviations 48
9.3 Methodology 50
9.4 Forecasting Methodology 50
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 50
9.4.2 Percent Drug-treated Patients 51
9.4.3 Percent Hormone Therapy-Treated Patients 51
9.4.4 General Pricing Assumptions 51
9.4.5 Individual Drug Assumptions 53
9.4.6 Generic Erosion 54
9.4.7 Pricing of Pipeline Agents 54
9.5 Physicians and Specialists Included in This Study 54
9.6 Survey of Prescribing Physicians 55
9.7 About the Authors 56
9.7.1 Authors 56
9.7.2 Global Head of Healthcare 56
9.8 About GlobalData 57
9.9 Contact Us 57
9.10 Disclaimer 57

List of Table


Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 12
Table 2: Global Variations in Recommendations on Routine PSA Screening 14
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 17
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 19
Table 5: Leading Treatments for Prostate Cancer, 2012 29
Table 6: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer - Current Level of Attainment 30
Table 7: Overall Unmet Needs, CRPC - Current Level of Attainment 31
Table 8: Clinical Unmet Needs - Gap Analysis, 2012 34
Table 9: Prostate Cancer - Phase III Pipeline, 2012 36
Table 10: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 36
Table 11: Product Profile - Alpharadin (radium-223 chloride) 38
Table 12: Alpharadin SWOT Analysis, 2012 42
Table 13: Global Sales Forecasts ($m) for Radium-223 Chloride, 2012-2022 43
Table 14: Physicians Surveyed, By Country 55

List of Chart


Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 18
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-2022 37

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *